Alan Napole

Alan Napole

Auto-generated profile, based on publicly available information

Alan Napole

Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2025 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Closed access
PDPierce Davis
Pierce Davis
GSGeorgios Sioutas
Georgios Sioutas
CRChethan Reddy
Chethan Reddy
ANAlan Napole
Alan Napole
RJRashad Jabarkheel
Rashad Jabarkheel
VSVisish M Srinivasan
Visish M Srinivasan
Background: Intracranial atherosclerotic disease (ICAD) is a leading cause of stroke, often refractory to aggressive medical therapy. Recent advancements in drug-eluting stents (DES) show promise for improved efficacy in intracranial applications relative to traditional ICAD treatments. Methods: We retrospectively collected all consecutive deployments of the Onyx Frontier [Medtronic, Santa Rosa, CA] stent in the setting of ICAD between August 2022 and August 2024 at six high-volume neuro-interventional centers across the US. Patients were included if their indication for stenting (eg, acute/recurrent stroke) was secondary to ICAD. Primary outcome was periprocedural stroke (<72 hours) and secondary outcomes included degree of pre- and post-stent vessel stenosis and National Institutes of Health Stroke Scale (NIHSS) scores at most recent follow-up. Secondary outcomes were assessed via paired t-tests. Results: Among 55 patients that met our inclusion criteria, the mean age was 62, mean presentation NIHSS was 10, and 40% were female. A total of 62 devices were used. Most common occlusion locations included the middle cerebral and internal carotid arteries. The periprocedural stroke rate was 10.9%, with a mortality rate of 1.8%. Mean vessel stenosis significantly decreased from 84.90% pre-stent to 2.00% post-stent (P<0.05). Mean NIHSS score improved from 10.37 preoperatively to 3.23 at follow-up (p<0.05). Procedural failure did not occur, however complications occurred in 16.4% of cases. Conclusion: Our findings suggest that stenting in this setting results in a lower periprocedural stroke rate than appreciated in historical trials such as SAMMPRIS and VISSIT. However, recent CASSISS and BASIS trials demonstrate far reduced periprocedural stroke rates in the context of submaximal angioplasty for ICAD. This, in conjunction with complication rate, suggest that the Onyx Frontier, while promising, may not offer a definitive solution to ICAD.

1 August 2025 in Neurology Clinical Practice
Verified
Journal Article
Closed access
CEColin A. Ellis
Colin A. Ellis
PLPatrick Z. Liu
Patrick Z. Liu
ANAlan Napole
Alan Napole
LDLydia Denison
Lydia Denison
NSNoor Fathima Shaik
Noor Fathima Shaik
DXDenise J. Xu
Denise J. Xu
Sleep is a critical component of health and recovery. Awakening sleeping patients for routine vital sign monitoring overnight is a common inpatient practice, but its benefits are uncertain. This study asked 3 questions: (1) How often are routine overnight vital signs abnormal? (2) How often are those abnormal vital signs clinically actionable? (3) Are there patients who may not need routine overnight vital sign monitoring? We analyzed observational retrospective data extracted from electronic health records of patients admitted to inpatient neurology floors at our institution between 2017 and 2024. We defined routine vital signs as collected by nursing assistants at least 3 hours apart. The outcome measure was an urgent clinical action (stat orders, rapid responses, or transfers to a higher level of care) within 1 hour of vital sign events. We compared the rate of urgent clinical actions after abnormal vital signs with the base rate of those events after normal vital signs. Statistical analysis used generalized estimating equations to account for repeated measures. We analyzed 102,184 routine vital sign events from 5,569 neurology admissions. In total, 9% of vital sign events were abnormal. The likelihood of urgent clinical actions increased after abnormal vital sign events, compared with after normal vital sign events during the day (4.3% vs 2.4%, odds ratio (OR) 1.8 [1.6-2.1]); at night (2.4% vs 0.9%, OR 2.8 [2.2-3.7]); during the night in low-risk patients with normal daytime vitals (2.0% vs 0.7%, OR 3.0 [1.8-4.9]); and at night in high-risk patients with abnormal daytime vitals (2.6% vs 1.1%, OR 2.5 [1.7-3.6]). The number needed to treat (NNT), i.e., the number of vital sign events needed to initiate 1 extra urgent clinical action above the base rate, was 1,856 [943; 4,598] in low-risk patients. The NNT for low-risk stroke patients was 1,570 [679; 4,707] and for general neurology patients was 2,231 [797; 5,423]. Urgent clinical actions attributable to abnormal routine vital signs were uncommon in neurology inpatients, especially overnight in patients with normal daytime vital signs. Determining the risks and benefits of routine overnight vital sign monitoring will help hospitals and health care providers move toward more patient-centered inpatient neurologic care.

9 February 2026 in Journal of Hospital Medicine
Verified
Journal Article
Open access
NSNoor Fathima Shaik
Noor Fathima Shaik
LDLydia Denison
Lydia Denison
GVG. M. Anya Venezia
G. M. Anya Venezia
LLLovisa Ljungberg
Lovisa Ljungberg
ALAlexa Lebrón‐Cruz
Alexa Lebrón‐Cruz
DXDenise J. Xu
Denise J. Xu
Background: Hospitalized patients often experience poor sleep, which is associated with worse health outcomes, increased rates of delirium, and readmissions. Objective: To improve overnight sleep for clinically stable general neurology patients at a single academic center. Methods: We conducted a quasi‐experimental pre‐post clinical trial of two sleep‐protective interventions: (1) a sleep‐friendly order set that reduced overnight interruptions by discontinuing vital sign checks/neurological examinations and retiming medications/blood draws; and (2) a “sleep menu” of comfort items. The primary outcome measure was sleep duration. Secondary outcomes were awakenings and patient responses to the Richards‐Campbell Sleep Questionnaire. Safety outcomes were rates of delirium, ICU transfers, and 30‐day readmissions. We compared the groups using linear mixed‐effects models to account for repeated measures (multiple nights per participant). Results: We analyzed data from 66 pre‐intervention participants (238 nights) and 61 post‐intervention participants (244 nights). The interventions did not increase sleep duration (pre‐intervention median 5.5 h [interquartile range (IQR) 4.0,6.6], post‐intervention median 5.4 h [4.1, 6.7], p = .84). There was marginal improvement in nightly awakenings (pre‐intervention 2 [1, 4], post‐intervention 2 [1, 3], p = .04). There were no significant differences in subjective sleep measures or safety outcomes. Targeted care team interruptions all significantly decreased post‐intervention, though staff intrusions remained a common patient‐reported barrier to sleep. Conclusion: Fragmented and reduced sleep was common in our general neurology population. Although our interventions did not improve sleep outcomes—apart from a modest drop in nocturnal awakenings—there was a significant decrease in care team interruptions. Poor inpatient sleep is multifactorial, and meaningful change likely requires comprehensive interventions.